Salud financiera de hoja de balance de Mentice

Salud financiera controles de criterios 5/6

Mentice tiene un patrimonio de los accionistas total de SEK159.0M y una deuda total de SEK0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son SEK322.5M y SEK163.6M respectivamente.

Información clave

Ratio deuda-patrimonio

kr0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	kr57.51m
Patrimonio	kr135.62m
Total pasivo	kr163.37m
Activos totales	kr298.99m

Actualizaciones recientes sobre salud financiera

No hay actualizaciones

Recent updates

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (SEK156.0M) de MN2 no cubren sus pasivos a corto plazo (SEK162.2M).

Pasivo a largo plazo: Los activos a corto plazo de MN2 (SEK177.1M) superan a sus pasivos a largo plazo (SEK2.1M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: MN2 está libre de deudas.

Reducción de la deuda: MN2 no ha tenido ninguna deuda en los últimos 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: Aunque no es rentable MN2 tiene suficiente cash runway para más de 3 años si mantiene su actual nivel positivo de flujo de caja libre.

Pronóstico de cash runway: MN2 no es rentable pero tiene suficiente cash runway para más de 3 años, debido a que el flujo de caja libre es positivo y crece un 27.2% al año.

Salud financiera de hoja de balance de Mentice

Salud financiera controles de criterios 5/6

Información clave

Actualizaciones recientes sobre salud financiera

Recent updates

Full year 2023 earnings released: kr0.11 loss per share (vs kr1.22 loss in FY 2022)

Mentice AB (publ) to Report Fiscal Year 2023 Final Results on Apr 24, 2024

Full year 2023 earnings released: kr0.11 loss per share (vs kr1.22 loss in FY 2022)

New minor risk - Market cap size

New major risk - Share price stability

Mentice Receives FDA 510(K) Clearance for Ankyras

Mentice Receives FDA 510(K) Clearance for Ankyras

Mentice AB (publ) (OM:MNTC) agreed to acquire All substantial assets of Biomodex from SIMARATO SAS for €0.2 million.

Director recently bought €71k worth of stock

Mentice (publ) Appoints Ulrika Drotz Voksepp as New Chief Financial Officer, Effective January 2, 2024

Mentice AB (Publ) Announces Board Appointments

Third quarter 2023 earnings released

Mentice AB (publ), Annual General Meeting, May 23, 2024

Mentice AB (publ) to Report First Half, 2024 Results on Jul 23, 2024

Mentice AB (Publ) Appoints of Jonatan Sjöström to Its Executive Management Group as Chief Operating Officer, Effective from September 14, 2023

New minor risk - Market cap size

Mentice AB (publ) Announces Chief Financial Officer Changes

Second quarter 2023 earnings released: EPS: kr0.06 (vs kr0.72 loss in 2Q 2022)

Insufficient new directors

Mentice AB (publ) Announces Resignation of Gunilla Andersson as Chief Financial Officer

Full year 2022 earnings released: kr1.22 loss per share (vs kr1.18 loss in FY 2021)

Full year 2022 earnings released: kr1.22 loss per share (vs kr1.18 loss in FY 2021)

Third quarter 2022 earnings released: kr0.30 loss per share (vs kr0.29 loss in 3Q 2021)

Mentice AB (publ) to Report First Half, 2023 Results on Jul 20, 2023

Mentice AB (publ), Annual General Meeting, May 11, 2023

Second quarter 2022 earnings released: kr0.71 loss per share (vs kr0.22 loss in 2Q 2021)

Mentice AB (publ) to Report Q4, 2022 Results on Feb 09, 2023

Mentice AB (publ) (OM:MNTC) completed the acquisition of All assets of the Ankyras software suite from Galgo Medical SL.

Mentice AB (publ) (OM:MNTC) agreed to acquire All assets of the Ankyras software suite from Galgo Medical SL for €2.775 million.

First quarter 2022 earnings released: kr0.30 loss per share (vs kr0.50 loss in 1Q 2021)

High number of new directors

Mentice AB (publ) Announces Change of Chairman of Board, Effective December 30, 2022

High number of new directors

Mentice Appoints Jan Grund Pedersen as New Vice President of Strategic Alliances & Business Development

Mentice AB (publ) to Report Fiscal Year 2021 Results on Apr 06, 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Third quarter 2021 earnings released: kr0.29 loss per share (vs kr0.014 loss in 3Q 2020)

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Chief Financial Officer Elisabet Lund has left the company

Second quarter 2021 earnings released: kr0.22 loss per share (vs kr0.46 loss in 2Q 2020)

Less than half of directors are independent

Second quarter 2021 earnings released: kr0.22 loss per share (vs kr0.46 loss in 2Q 2020)

First quarter 2021 earnings released: kr0.50 loss per share (vs kr0.21 loss in 1Q 2020)

New 90-day low: €7.52

Full year 2020 earnings released: kr0.54 loss per share (vs kr1.05 loss in FY 2019)

Revenue misses expectations

Mentice Announces Executive Appointments

Mentice AB (publ) to Report Fiscal Year 2020 Results on Feb 04, 2021

Third quarter 2020 earnings released: kr0.01 loss per share

Revenue misses expectations

Mentice AB (Publ) Announces Nomination Committee

New 90-day low: €7.00

Mentice AB (publ) (OM:MNTC) entered into agreement to acquire substantially all assets of EQIP, Inc. for $0.25 million.

Mentice AB (publ) (OM:MNTC) signed a definitive agreement to acquire Substantial All Assets of Vascular Simulations LLC for $6 million.

Mentice AB (publ) to Report Q2, 2020 Results on Aug 13, 2020

Mentice AB (publ) to Report Q3, 2020 Results on Nov 12, 2020

New 90-day high - €7.36

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera